AFT Pharmaceuticals - Big win with Maxigesic Rapid’s FDA nod
AFT Pharmaceuticals (AFT) has announced it has received FDA approval for Maxigesic Rapid tablets, a quick-release version of its flagship Maxigesic...
263 Views
AFT Pharmaceuticals - Portfolio expansion with new in-licensing deal
AFT Pharmaceuticals continues to strengthen its R&D pipeline with the announced in-licensing agreement with Latitude Pharmaceuticals (a...
474 Views
AFT Pharmaceuticals - Maxigesic IV expands into East European markets
AFT Pharmaceuticals has announced an exclusive licensing and distribution agreement for the Maxigesic intravenous (IV) formulation with Salus...
365 Views
AFT Pharmaceuticals - Progressive outlook for CY23
AFT Pharmaceuticals has presented its key CY22 highlights and strategic priorities for CY23 in a letter to investors. In addition to new product...
558 Views
AFT Pharmaceuticals: 1H23 Result — A Few Sniffles
AFT Pharmaceuticals' (AFT) 1H23 result highlighted ongoing strong underlying revenue momentum which was ahead of our expectations, but this was...
393 Views